A post hoc evaluation of the shift in spasticity category in individuals with multiple sclerosis-related spasticity treated with nabiximols

BACKGROUND: Over 80% of individuals with multiple sclerosis (MS) experience MS-associated spasticity (MSS). In many European countries, after failure of first-line treatments, moderate or severe MSS can be treated with nabiximols, a cannabis-based add-on treatment. OBJECTIVE: This post hoc analysis...

Descripción completa

Detalles Bibliográficos
Autores principales: Chisari, Clara Grazia, Guadagno, Joe, Adjamian, Peyman, Vila Silvan, Carlos, Greco, Teresa, Bagul, Makarand, Patti, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515604/
https://www.ncbi.nlm.nih.gov/pubmed/37745913
http://dx.doi.org/10.1177/17562864231195513

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515604/
https://www.ncbi.nlm.nih.gov/pubmed/37745913
http://dx.doi.org/10.1177/17562864231195513

Ejemplares similares